RCA / Cell Based Systems / Agency for the Evaluation / / /
Event
Product Issues / /
Facility
Canary Wharf / / /
IndustryTerm
immuno-chemical tests / cell bank / individual products / manufacturing changes / derived protein products / biological products / final product / therapies for certain human diseases / production/manufacturing process / Cell-based products / gene transfer product / end products / replication systems / physico-chemical and immunological characteristics / gene transfer medicinal product / final gene transfer product / e.g. gene transfer products / authorisation applications / human medicinal products / transfer products / chemical / final processed product / gene transfer medicinal products / gene transfer products / cell bank system / final transfer product / pharmaceutical quality / medicinal products / salt solution / manufacturing process / marketing authorisation applications / /
MedicalCondition
cancer / disease / Agents Causing Spongiform Encephalopathy / same disease / cases replication-competent viruses e.g. vaccinia virus / certain human diseases / infection / herpes simplex virus / /
MedicalTreatment
antibiotics / vaccination / /
Organization
COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS / EFFICACY WORKING PARTY / BIOTECHNOLOGY WORKING PARTY / SAFETY WORKING PARTY / European Agency for the Evaluation of Medicinal Products Evaluation of Medicines / WRITTEN PROCEDURE WITH SAFETY WORKING PARTY / / /
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 24 April 2001 CPMP/BWP